Hudson College of Public HealthUniversity of Oklahoma Health Sciences Center Oklahoma City OK.
The Feinstein Institutes for Medical Research and Zucker School of Medicine at Hofstra/Northwell Anticoagulation and Clinical Thrombosis Services Department of Medicine Northwell Health at Lenox Hill Hospital New York NY.
J Am Heart Assoc. 2021 Feb;10(5):e019459. doi: 10.1161/JAHA.120.019459. Epub 2021 Feb 15.
Background Asymptomatic proximal deep vein thrombosis (DVT) is an end point frequently used to evaluate the efficacy of anticoagulant thromboprophylaxis in medical patients. Recently, the clinical relevance of asymptomatic DVT has been challenged. Methods and Results The objective of this study was to evaluate the relationship between asymptomatic proximal DVT and all-cause mortality (ACM) using a cohort analysis of a randomized trial for the prevention of venous thromboembolism (VTE) in acutely ill medical patients. Patients who received at least 1 dose of study drug and had an adequate compression ultrasound examination of the legs on either day 10 or day 35 were categorized into 1 of 3 cohorts: no VTE, asymptomatic proximal DVT, or symptomatic DVT. Cox proportional hazards model, with adjustment for significant independent predictors of mortality, were used to compare the incidences of ACM. Of the 7036 patients, 6776 had no VTE, 236 had asymptomatic DVT, and 24 had symptomatic VTE. The incidence of ACM was 4.8% in patients without VTE. Both asymptomatic proximal DVT (mortality, 11.4%; hazard ratio [HR], 2.31; 95% CI, 1.52-3.51; <0.0001) and symptomatic VTE (mortality, 29.2%; HR, 9.42; 95% CI, 4.18-21.20; <0.0001) were independently associated with significant increases in ACM. The analysis was post hoc, and ultrasound results were not available for all patients. Adjustment for baseline variables significantly associated with ACM may not fully compensate for differences. Conclusions Asymptomatic proximal DVT is associated with higher ACM than no VTE and remains a relevant end point to evaluate the efficacy of anticoagulant thromboprophylaxis in medical patients. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT00571649.
无症状的近端深静脉血栓(DVT)是评估抗凝药物预防医学患者血栓栓塞事件疗效的常用终点指标。然而,无症状 DVT 的临床意义最近受到了质疑。
本研究旨在通过对急性病医学患者静脉血栓栓塞症(VTE)预防的随机试验进行队列分析,评估无症状近端 DVT 与全因死亡率(ACM)之间的关系。接受至少 1 剂研究药物且在第 10 天或第 35 天腿部压缩超声检查充分的患者,分为 3 个队列之一:无 VTE、无症状近端 DVT 或有症状 DVT。采用 Cox 比例风险模型,对死亡率的显著独立预测因素进行调整,比较 ACM 的发生率。在 7036 例患者中,6776 例无 VTE,236 例无症状 DVT,24 例有症状 DVT。无 VTE 患者的 ACM 发生率为 4.8%。无症状近端 DVT(死亡率 11.4%,风险比 [HR] 2.31,95%CI 1.52-3.51;<0.0001)和有症状 DVT(死亡率 29.2%,HR 9.42,95%CI 4.18-21.20;<0.0001)与 ACM 显著增加独立相关。该分析为事后分析,并非所有患者均行超声检查。对与 ACM 显著相关的基线变量进行调整,可能无法完全弥补差异。
无症状近端 DVT 与 ACM 升高相关,且高于无 VTE,仍是评估抗凝药物预防医学患者血栓栓塞事件疗效的重要终点指标。